Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMNIYPS)

Drug Name	PF-06835375 DMNIYPS

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Immune thrombocytopenic purpura	DISYJ8IL	3B64.13	Phase 2	[1]
------------------------------------------------------------------------------------

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Phase 1	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05070845) AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT03334851) A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS. U.S.National Institutes of Health.